G(old) Generation : creació i bíblia d'un nou format televisiu

Projecte de creació d'un format televisiu pertanyent al gènere docu-reality. El format pretén trencar amb els estereotips de la tercera edat i demostrar que qualsevol persona és capaç de fer allò que vol si s'ho proposa, independentment dels estigmes de l'edat. El present Treball de Fi de Grau incorpora tota la teoria i documentació específica pel desenvolupament del format, a més del material necessari per la seva posterior venda a la indústria. També inclou el teaser del format.Proyecto de creación de un formato televisivo perteneciente al género docu-reality. El formato pretende romper con los estereotipos de la tercera edad y mostrar que cualquier persona es capaz de hacer todo lo que quiere si se lo propone, independientemente de los estigmas de la edad. El presente Trabajo de Fin de Grado incorpora toda la teoría y documentación específica para el desarrollo del formato, además del material necesario para la posterior venda en la industria. También incluye el teaser del formato.Creation project of a television format belonging to the docu-reality genre. The format intends to deconstruct the stereotypes of the old age and prove that anyone is capable of doing everything they have always been curious about, regardless of the age stigmas. The present Degree's Thesis includes all the theory and specific documentation for the development of the format, as well as the necessary material for its subsequent sale into the industry. It also includes the format's teaser

(In)visible city

Treball de l'assignatura Art Contemporani del Grau en Comunicació Audiovisual, curs 2019-2020. Professora: Sandra Álvaro Sánche

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols